beat rais ep
lower tax
revenue consensu ep lilli
maintain revenue guidanc provid dec despit fx
chang rais non-gaap ep tax rate declin
ep guidanc provid dec rais lower tax revenu
guidanc midpoint in-lin con
ep guidanc prev midpoint
con tax rate new
guidanc origin guidanc
revenu project oper incom line due higher
sg ep financi item revenu
con ep con
i/ yoy growth nutshel rev gross profit
oper inc pre-tax net inc ep ep upsid vs
product revenu upsid highlight verzenio revenu
trulic revenu humulin
revenu humalog revenu
alimta revenu ciali
revenu forteo revenu
revenu
product revenu downsid highlight olumi revenu
lartruvo revenu taltz
revenu jardiance/glyxambi revenu
tradjenta revenu
cyramza revenu basaglar revenu
portrazza revenu
anim health revenu
catalyst ahead baricitinib jak fda action ra mid admelog
sanofi approv dec launch uptak elanco anim health
financi strateg updat relat exit decis mid verzenio
sale ramp fda action breast cancer estimate galcanezumab
cgrp pdufa migrain prevent oct estimate
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
per share equat approxim pre-tax
olumi bari high royalti
jardiance/glyxambi gm receiv gp bi
tradjenta/jenta gm receiv gp bi
basaglar estimate gm share gp bi
olumi bari high royalti
jardiance/glyxambi gm receiv gp bi
tradjenta/jenta gm receiv gp bi
basaglar estimate gm share gp bi cog
pt base case ep premium peer mean
due lilli better growth prospect ep compound-annual-growth-rate vs group average off-set
uncertainti around next key event novo oral sema ph bari fda action
see solid growth prospect balanc premium valuat
risk achiev price target
upsid risk posit financi result project new product revenu
disappoint compel extern strateg action
downsid risk neg fda action bari compet drug surpris upsid
financi result fall short expect face us price pressur pipelin
